Carbenoxolone sodium (Biogastrone) has been used for several years in the treatment of gastric ulcer. The drug was considered unsuitable for the treatment of duodenal ulceration, as it is rapidly absorbed from the stomach and is thought to produce healing by a direct action on the mucosa. Recently, however, a capsule has been developed which is claimed to release the carbenoxolone at the pylorus, and to be of value in the medical management of duodenal ulcers (Craig, Hunt, Kimerling, and Parke, 1967) .
Hypertension, oedema, or potassium loss has been reported in up to 50% of patients receiving 300 mg. of carbenoxolone sodium daily (Doll, Hill, and Hutton, 1965; Horwich and Galloway, 1965; Turpie and Thomson, 1965) , and one case has been observed in which severe hypokalaemia, flaccid quadruparesis, and myoglobinuria developed on the 38th day of treatment (Mohamed, Chapman, and Crooks, 1966) . On the other hand, the positioned-release capsules (Duogastrone) in a dose of 200 mg. daily produced mild hypokalaemia and fluid retention in only 2 out of 22 patients (Montgomery, Lawrence, Manton, Mendl, and Rowe, 1968) and no side-effects in another group of 32 patients (Craig et al., 1967) . The following case illustrates that carbenoxolone positionedrelease capsules can occasionally produce serious side-effects, which may develop several days after the drug has been stopped.
CASE REPORT
The patient, a 35-year-old man, was admitted to hospital two days after the sudden onset of severe weakness in his legs and back. The weakness had been preceded by vague aching pains in the legs and shoulders for five days. The only previous illness was a duodenal ulcer for which he had taken 200 mg. of Duogastrone daily for six weeks, this treatment being stopped 11 days before his present admission to hospital. He had not taken any other drugs.
On physical examination there was marked weakness of the muscles of the legs and back and he was unable to 'stand or sit up in bed. Power in the arms was only slightly impaired. The deep tendon reflexes were hypoactive, but there was no other abnormality.
Investigations.-The ha'emoglobin was 17-0 g./100 ml., white cells 8,700/cu. mm., erythrocyte sedimentation rate 6 mm. in one hour, and the blood film normal. Spectroscopic examination of the serum showed no abnormal blood pigments. The serum electrolytes (mEq/l.) were: sodium 140, potassium 19, chloride 92, COs 37. The serum urea was 23 mg., albumin 4-3 g., and globulin 1-9 g./100 ml.; electrophoresis of the serum proteins was normal. The serum aldolase was 123 units (normal range 3-12 units), and the creatine phosphokinase 265 units/ml. (normal range 0-20 units). Microscopical examination of the urine was normal, but there was slight albuminuria and the occult test was positive; the urine samples were inadvertently thrown away before spectroscopic examination was considered. The cerebrospinal fluid was normal.
He was treated with 8 g. of potassium chloride daily by drip infusion for four days, following which the serum potassium level had risen to 3-1 mEq/l. Treatment was continued with potassium chloride 4-8 g. daily by mouth, and five days later the serum potassium level was 3-8 mEq/l. He made a rapid clinical improvement and was able to return home, fully ambulant, 10 days after starting potassium therapy. The dose of potassium chloride was then reduced to 1-2 g. daily, and when he was seen in the outpatient clinic two weeks later he had made almost a complete recovery. The serum potassium was 4 9 mEq/l., the aldolase 13 units/ml., and the creatine phosphokinase 18 units/ml. The urine was normal.
COMMENT Carbenoxolone sodium was the only medication taken by this patient, and it seems reasonable to suppose that this drug was responsible for the hypokalaemia and muscle paresis. There was no oedema or rise in the blood pressure, which emphasizes that severe toxicity may occur in the absence of these two signs.
The raised serum muscle enzymes and the indirect signs of myoglobinuria-a positive urine occult test in the absence of haematuria and haemolysis-provide strong evidence of muscle necrosis. Such severe muscle damage resulting from carbenoxolone therapy has to my knowledge been described previously in only one case by Mohamed et al. (1966) , and they were uncertain whether this was due entirely to the hypokalaemia or at least partly to a direct "steroid-like" effect of the drug on the muscles.
The muscle paresis developed acutely nine days after stopping Duogastrone therapy, and particularly as the patient had not been under my care for the treatment of duodenal ulcer, the full diagnostic implication of the previous treatment was not evident immediately. In the light of this case, therefore, it is important to recognize that the toxic effects of this preparation of carbenoxolone can be delayed. Although Craig et al. (1967) found that the capsules were reliable in releasing their contents at the pylorus, Langman (1968) showed that they rarely entered the pyloric antrum, but tended to float on the surface of the gastric contents. The delayed onset of toxic symptoms may therefore have been due to the capsules failing to burst at the pylorus and being retained in the stomach for a few days.
